Manufacturing site to be built in partnership with IDT Biologika to help defuse row with EU over supply
AstraZeneca has unveiled plans to build a new Covid-19 vaccine manufacturing facility in partnership with IDT Biologika at the German firm’s Dessau site, in a move aiming to speed up production and defuse a row with the EU over supplies.
IDT Biologika, one of AstraZeneca’s manufacturing partners, provides glass vials and injects the liquid vaccine – which is made at other European sites – into the vials, before capping and boxing them.
